Novel Targeted Therapy Reduces Chemoresistance In Mouse Model Of Melanoma
Wednesday, June 11, 2008 - 07:21
in Biology & Nature
A novel small molecule inhibitor reduced both endogenous and drug-induced resistance to chemotherapy in a mouse model of melanoma. The NF-ºB pathway is often active in human cancers and promotes resistance to cytotoxic chemotherapy drugs. Some cytostatic drugs, such as doxorubicin, induce NF-ºB pathway activity.
Read the whole article on Science Daily
More from Science Daily
Related
- CSHL team develops mouse models of leukemia that predict response to chemotherapyTue, 31 Mar 2009, 17:44:19 EDT
- Scientists create mouse model of melanoma that generates hope for the use of targeted therapiesThu, 12 Mar 2009, 16:58:08 EDT
- Novel enzyme inhibitor paves way for new cancer drugFri, 16 May 2008, 10:42:42 EDT
- CSHL scientists correlate enzyme expression levels with chemotherapy drug responseFri, 18 Jul 2008, 12:07:44 EDT
- Targeted therapy plus chemotherapy may pack 1-2 punch against melanomaThu, 15 May 2008, 7:28:43 EDT